Global Embolization Particle Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Embolization Particle Market Analysis

The embolization particle market has seen significant growth due to the increasing prevalence of conditions such as liver cancer, peripheral vascular diseases, and uterine fibroids, which require embolization treatments. Embolization, a procedure where particles are used to block blood flow to certain areas, is increasingly preferred due to its minimally invasive nature and effectiveness. The growing demand for interventional radiology procedures is a key driver of market expansion. Recent advancements include the development of drug-eluting beads (DEBs), which combine embolization with targeted drug delivery for more effective treatments. Moreover, the rising number of hospitals and specialized centers offering embolization procedures, coupled with innovations in embolization particle materials (microspheres, PVA particles), is expected to propel market growth. However, challenges such as the high cost of embolization treatments and limited access in some regions may hinder growth. The market is expected to continue expanding with the increasing adoption of these technologies in both developed and emerging markets.

Embolization Particle Market Size

The global embolization particle market size was valued at USD 2.40 billion in 2024 and is projected to reach USD 5.67 billion by 2032, with a CAGR of 11.32% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Embolization Particle Market Trends

“Development of Personalized Treatments”

The embolization particle market is experiencing significant growth driven by the increasing demand for minimally invasive treatments for conditions such as liver cancer, uterine fibroids, and peripheral vascular diseases. Innovations in embolization particle materials, including drug-eluting beads (DEBs), are transforming treatment approaches by combining embolization with targeted drug delivery. One major trend is the shift toward personalized treatments, where physicians select specific embolization particles based on the patient’s condition and tumor characteristics. Additionally, advancements in microsphere and PVA particle technology are enhancing the precision and effectiveness of embolization procedures. With growing investments in interventional radiology and an expanding patient base, the market for embolization particles is expected to continue its upward trajectory, especially in developed and emerging healthcare markets.

Report Scope and Embolization Particle Market Segmentation        

Embolization Particle Market Definition

Embolization particles are small, biocompatible materials used in medical procedures to block blood flow to a specific area of the body, typically in the treatment of tumors or vascular conditions. These particles are injected into blood vessels through a catheter, where they obstruct the flow of blood to a targeted region, such as a tumor or abnormal vascular structure, leading to tissue ischemia or shrinkage. Embolization particles can vary in composition, including materials such as microspheres, drug-eluting beads, polyvinyl alcohol (PVA) particles, and gel foam, each designed to provide different therapeutic benefits depending on the condition being treated.

Embolization Particle Market Dynamics

Drivers

• Rising Incidence of Cancer and Tumors

The rising number of cancer diagnoses, particularly liver and lung cancers, has significantly increased the demand for effective treatments such as embolization particle-based therapies. These treatments are primarily used to target tumors via procedures such as transarterial embolization (TAE) and transarterial chemoembolization (TACE), which are minimally invasive yet highly effective in delivering localized treatment. As these procedures help to block the blood supply to tumors, they prevent cancer cells from growing and spreading. The growing prevalence of cancers, coupled with the effectiveness of embolization techniques, is a key driver of the embolization particle market, expanding its adoption in oncology treatments.

• Technological Advancements in Embolization Materials

The development of advanced embolization particles, such as drug-eluting beads and microspheres, is significantly enhancing the precision and effectiveness of embolization treatments. These innovative particles allow for targeted delivery of therapy directly to the tumor site, improving treatment outcomes by minimizing damage to surrounding healthy tissues. Drug-eluting beads, for instance, release chemotherapy drugs over time, providing sustained local treatment. These advancements in embolization technology are expanding the range of applications for embolization techniques, particularly in treating tumors such as those found in the liver and lungs. The growing availability of such advanced particles is a key driver of market growth, increasing their adoption in clinical practice.

Opportunities

• Increased Incidence of Target Diseases

The rising global incidence of tumors, including liver cancer, vascular malformations, and uterine fibroids, is driving the demand for embolization procedures. These conditions, particularly liver cancer, are among the leading causes of morbidity and mortality, creating a significant need for effective treatment options. Embolization therapies, which block blood flow to tumors, provide a targeted, minimally invasive approach to treat these diseases. As cancer rates and vascular disorders increase globally, the demand for embolization treatments is expected to grow substantially. This trend represents a key market opportunity for companies involved in the development and distribution of embolization particles, as the need for these treatments continues to expand.

• Rising Healthcare Investments

Increasing healthcare spending, especially in emerging economies, is significantly expanding access to advanced medical treatments such as embolization. As these regions experience economic growth, governments and private sectors are investing heavily in healthcare infrastructure, improving facilities, and expanding healthcare coverage. This investment is coupled with enhanced diagnostic capabilities, enabling earlier detection and more effective treatment of conditions such as tumors and vascular diseases. With the rising adoption of minimally invasive procedures, embolization therapies are becoming more accessible to a broader patient population. This trend presents a substantial market opportunity for companies to expand their presence in these growing regions, driving the demand for embolization particles.

Restraints/Challenges

• Competition from Alternative Treatments

Other treatment options, such as surgery, radiation therapy, and chemotherapy, continue to be widely used for managing conditions such as tumors and uterine fibroids, posing significant competition to embolization therapies. These traditional treatments have established efficacy and are often preferred due to their long-standing clinical use and familiarity among healthcare providers. As a result, embolization particles, despite being minimally invasive, may face challenges in convincing both patients and doctors to choose them over more conventional options. The competition from these established treatments can slow the adoption of embolization procedures, limiting the overall growth potential of the embolization particle market.

•  Limited Product Availability

The availability of advanced embolization particles may be constrained in certain regions due to supply chain disruptions, manufacturing challenges, or regulatory barriers. These factors can limit the timely production and distribution of embolization products, particularly in emerging markets where infrastructure and logistics may be underdeveloped. Regulatory hurdles, such as lengthy approval processes and stringent requirements for medical devices, can further delay market entry and restrict access to new embolization therapies. As a result, patients in these regions may not have access to the latest treatments, hindering the overall growth and reach of the embolization particle market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Embolization Particle Market Scope

The market is segmented on the basis of product type, application, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Radioembolization Spheres
• Microspheres
• Drug Eluting Beads (DEBs)
• PVA Particles and Gelfoam Particles
• Others

Application

• Peripheral Vascular Disease
• Neurology
• Oncology
• Urology
• Others

End User

• Hospitals
• Clinics
• Ambulatory Centers
• Others

Embolization Particle Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, application, and end user referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the embolization particle market due to its robust economic environment and the rapid growth of the healthcare sector. The region's emphasis on research and development, coupled with substantial investments in healthcare infrastructure, drives innovation in advanced diagnostic and treatment technologies. This focus on modernizing healthcare further strengthens the demand for embolization treatments.

The Asia-Pacific region is anticipated to experience substantial growth from 2025 to 2032, driven by a rising patient population, particularly those with cancer, in emerging economies such as India. Increasing healthcare access and awareness in these countries are contributing factors to this growth. As cancer rates rise, the demand for effective treatment options, including embolization, is expected to grow significantly in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Embolization Particle Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Embolization Particle Market Leaders Operating in the Market Are:

• Sirtex SIR-Spheres Pty Ltd. (Australia)
• Guerbet (France)
• Boston Scientific Corporation (U.S.)
• Medtronic (U.S.)
• Merit Medical Systems (U.S.)
• BTG (U.K.)
• KAVYA PHARMA (India)
• Varian Medical Systems, Inc. (U.S.)
• Terumo Medical Corporation (Japan)
• Cook (U.S.)

Latest Developments in Embolization Particle Market

• In May 2023, Merit Medical Systems, Inc. acquired the BioSentry® Biopsy Tract Sealant System and several dialysis catheter devices from AngioDynamics, Inc. for $100 million in cash. Additionally, Merit Medical made a $32.5 million cash payment to Bluegrass Vascular Technologies, Inc. for the Surfacer® Inside-Out® Access Catheter System. These strategic acquisitions are aimed at expanding Merit’s portfolio in the vascular and biopsy tract management sectors
• In June 2023, Terumo Aortic launched its global Post-Approval Study (PAS), known as EXTEND, which centers on the Thoraflex Hybrid device. This device is the only Frozen Elephant Trunk (FET) device approved by the US Food and Drug Administration (FDA) for treating patients with complex aortic arch diseases. The study aims to further evaluate the device's effectiveness and long-term outcomes in this patient population
• In December 2022, Sirtex Medical and Grand Pharmaceutical Group Limited received approval from the Chinese National Medical Products Administration for their SIR-Spheres® Y-90 resin microspheres. This milestone marked the first successful selective internal radiation therapy (SIRT) procedure using SIR-Spheres in China. The approval opens up new opportunities for the treatment of liver cancer patients in the region using this advanced therapy

SKU-59609